Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Polygenic risk score-based phenome-wide association for glaucoma and its impact on disease susceptibility in two large biobanks

Fig. 2

Significance plot for all phenotypes for POAG PRS, grouped by disease categories from discovery set and replication set. A Significance plot for all phenotypes for POAG PRS, grouped by disease categories from UK Biobank. PheCodes are organized and plotted by disease category on the x-axis, and the y-axis represents the − log10 of uncorrected P values of two-sided test for linear regression between POAG PRS and each of the phenotype. Each point represents a single PheCode, and the color indicates their corresponding categories. The horizontal line is marked at the Bonferroni threshold of significance for multiple testing (P < 5.21 × 10−5). The representative significant associations in each category are annotated in the figure. The direction of each arrowhead corresponds to increased risk (up) or decreased risk (down). The discovery samples consist of 377,852 participants in the UK Biobank and the exact sample size for each phenotype are presented in Additional file 2. B Significance plot for all phenotypes for POAG-PRS, grouped by disease categories from Penn Medicine Biobank (replication sample). PheCodes are organized and plotted by category on the x-axis, and the y-axis represents the − log10 of uncorrected P values of two-sided test for linear regression between POAG PRS and each of the phenotype. Each point represents a single PheCode, and the color indicates their corresponding categories. The horizontal red line is marked at the Bonferroni threshold of significance for multiple testing (P < 6.52 × 10−5). The representative significant associations in each category are annotated in the figure. The direction of each arrowhead corresponds to increased risk (up) or decreased risk (down). The replication samples consist of 27,933 participants and the exact sample size for each phenotype is presented in Additional file 2 . 

Back to article page